DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside

DBV Technologies is rated a buy, with a 24% upside to a $17 FY 2027 price target as Viaskin nears BLA submission. DBVT’s transition from research to commercial readiness is evident, with rising sales/marketing spend and declining research tax credits signaling operational progress. The key catalyst is the planned Q3 2026 BLA submission, expected to trigger a 10-month FDA review and potential commercial launch in 2027. Risks remain moderate to high, primarily regulatory delays and uncertain market adoption, given prior sluggish uptake of competing therapies like Palforzia. DBV Technologies is a clinical-stage biotech company developing Viaskin, a proprietary dermal patch to help train patients to tolerate food allergies, primarily peanut allergy. This non-invasive process, called Epicutaneous Immunotherapy (EPIT), remains a major medical breakthrough.